Herman WaldmannFRSFMedSci (born 27 February 1945) is a Britishimmunologist known for his work on therapeuticmonoclonal antibodies. As of 2013, he is Emeritus Professor of Pathology at the Sir William Dunn School of Pathology at theUniversity of Oxford.
Waldmann grew up in north-east London, and was a student at theSir George Monoux Grammar School,Walthamstow andSidney Sussex College, Cambridge. He worked in the Department of Pathology of theUniversity of Cambridge from 1973, becoming head of the Immunology Division in 1989. In 1994, he took up the position of head of the Sir William Dunn School of Pathology at theUniversity of Oxford.[1] He is a fellow ofLincoln College.[2]
Waldmann's research has focused onimmunological tolerance and the harnessing of tolerance mechanisms to treat autoimmune diseases and enable transplant acceptance. He is best known for his work on therapeuticmonoclonal antibodies and their use to achieve tolerance, particularly Campath-1, now licensed as Lemtrada for the treatment of Multiple Sclerosis.
Waldmann was elected a Fellow of theRoyal Society in 1990.[3] He delivered the 1992Bradshaw Lecture at the Royal College of Physicians.[4] In 1998, he was a founding fellow of theAcademy of Medical Sciences.[5] In 2008, he was awarded an honorary doctorate ScD(Hon) by the University of Cambridge.[6] In 2010 he became a Fellow of the Royal College of Physicians (FRCP). In 2005 he received the Jose Carreras award from the European Hematology Association and also, the Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation. In 2007 he was awarded Thomas E Starzl Prize in Surgery and Immunology, and also, the Scrip Lifetime Achievement award from the Pharmaceutical industry. He is an honorary fellow of Queen Mary Westfield College, and of both King's College and Sidney Sussex College, Cambridge.He is an honorary member of theBritish Society for Immunology.[7] In 2023 he was awarded theRoyal Medal of the Royal Society.[8]
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
